Form 4: DENTSPLY SIRONA Officer Awarded Equity

DENTSPLY SIRONA's VP, Chief Accounting Officer, Kevin Czerney, received grants of 13,690 Restricted Stock Units and 10,400 stock options.

Summary

• Kevin Czerney, VP, Chief Accounting Officer, was granted 13,690 Restricted Stock Units (RSUs) of DENTSPLY SIRONA Inc. common stock on March 4, 2026.
• These RSUs vest in annual one-third increments over a three-year period, concluding on March 4, 2029.
• Czerney also received a grant of 10,400 stock options on March 4, 2026, with an exercise price of $14.78.
• The stock options vest in annual one-third increments over a three-year period, ending March 4, 2029, and have an expiration date of March 4, 2036.
• The exercise price for the stock options is 110% of the closing price of the common stock on the grant date.
• Following these transactions, Czerney beneficially owns 41,268.908 shares of common stock and 10,400 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive development, as it indicates continued alignment of a key executive's interests with long-term shareholder value through performance-based equity awards.

Positives

• Increased alignment of management's interests with shareholders through equity awards.
• Retention of key executive talent through long-term incentive compensation.

Negatives

• Potential for minor dilution from the issuance of new shares upon RSU vesting and option exercise.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants to executives are a standard practice across industries, particularly in the healthcare and dental technology sectors, to incentivize long-term performance and align executive interests with shareholder value. This specific grant is consistent with typical executive compensation structures.

Comparison to Industry Standards

• Equity compensation, including RSUs and stock options, is a common component of executive remuneration packages in publicly traded companies, comparable to practices at peers like Align Technology (ALGN) or Zimmer Biomet (ZBH).
• The three-year vesting schedule is standard for long-term incentive plans, aiming to retain talent and encourage sustained performance, similar to programs seen at major medical device companies.
• The stock option exercise price being 110% of the grant date closing price is a common feature for premium options, designed to provide a stronger incentive for stock price appreciation.

Related Party Transactions

• The grant of Restricted Stock Units and stock options to Kevin Czerney, an officer of DENTSPLY SIRONA Inc., constitutes a transaction between the company and a related party as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting/exercise, but also increased alignment of executive incentives with shareholder value creation.
• Employees: Standard executive compensation practices can set a precedent for other employees' incentive structures.
• Management: Strengthens retention and motivation for the VP, Chief Accounting Officer.

Next Steps

• Continued vesting of Restricted Stock Units and stock options over the next three years, with final vesting on March 4, 2029.
• Potential exercise of stock options by Kevin Czerney before their expiration on March 4, 2036.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity grants. While it shows continued alignment of management interests with shareholders, it does not present new information that would fundamentally alter the investment thesis for DENTSPLY SIRONA Inc. Therefore, a "hold" recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

DENTSPLY SIRONA, XRAY, Kevin Czerney, Form 4, Restricted Stock Units, RSU, Stock Options, Insider Trading, Equity Award, Executive Compensation, Beneficial Ownership